ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,169.92
0.25%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Amgen Inc (AMGN)

  7. Amgen Inc (AMGN) News

Amgen (AMGN)

Amgen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMGN
DateTimeSourceHeadlineSymbolCompany
14/06/202421:21PR Newswire (US)FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASENASDAQ:AMGNAmgen Inc
12/06/202422:23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AMGNAmgen Inc
12/06/202414:00PR Newswire (US)AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024NASDAQ:AMGNAmgen Inc
05/06/202421:00PR Newswire (US)AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
05/06/202414:00PR Newswire (US)AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)NASDAQ:AMGNAmgen Inc
05/06/202400:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202400:22Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
03/06/202422:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMGNAmgen Inc
03/06/202421:00PR Newswire (US)AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
28/05/202414:00PR Newswire (US)AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024NASDAQ:AMGNAmgen Inc
19/05/202422:15PR Newswire (US)NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPDNASDAQ:AMGNAmgen Inc
16/05/202423:46PR Newswire (US)FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERNASDAQ:AMGNAmgen Inc
15/05/202423:45PR Newswire (US)AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024NASDAQ:AMGNAmgen Inc
10/05/202421:02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMGNAmgen Inc
10/05/202400:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
10/05/202400:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
10/05/202400:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
10/05/202400:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
10/05/202400:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
10/05/202400:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
 Showing the most relevant articles for your search:NASDAQ:AMGN

Your Recent History

LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
PHNX
Phoenix
LSE
SDRY
Superdry
LSE
AFC
Afc Energy
LSE
HE1
Helium One Global
LSE
HUM
Hummingbird Resources
LSE
GPM
Golden Prospect Precious...
LSE
SRSP
Sirius Petroleum
LSE
FUM
Futura Medical
LSE
ENET
Ethernity Networks
LSE
VOD
Vodafone
LSE
JIM
Jarvis Securities
LSE
IES
Invinity Energy Systems
LSE
LLOY
Lloyds Banking
LSE
VAST
Vast Resources
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved